Research statistics
Mazdutide research: publications and trials
At a glance
Publications, all years
49
Since 2021
Publications in 2026 so far
23
Through November 15, 2026
Human clinical research
30.6%
15 of 49 classified
Registered clinical trials
46
ClinicalTrials.gov
Randomized controlled trials
12
Publications reporting an RCT in people
Systematic reviews and meta-analyses
14
Preclinical studies
10.2%
4 animal · 1 in vitro · 0 computational
Records that only mention it
11
Not counted above
Status in the library: In clinical trials. Groups: GLP-1 receptor agonists.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Mazdutide publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2021 | 1 | 0 | 0 | 0 | 1 |
| 2022 | 2 | 0 | 0 | 0 | 2 |
| 2023 | 1 | 0 | 0 | 0 | 1 |
| 2024 | 1 | 0 | 7 | 0 | 8 |
| 2025 | 6 | 2 | 4 | 2 | 14 |
| 2026 (to date) | 4 | 3 | 14 | 2 | 23 |
Study types
| Randomized controlled trial | 12 |
|---|---|
| Review | 11 |
| Meta-analysis | 9 |
| Systematic review | 5 |
| Animal study | 4 |
| Editorial, letter or other | 4 |
| Case report | 2 |
| Other clinical trial | 1 |
| In vitro study | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Metabolic health | 38 |
|---|---|
| Obesity and weight management | 34 |
| Endocrinology | 20 |
| Gastrointestinal | 5 |
| Cardiovascular | 4 |
| Cognitive health | 1 |
| Immune system | 1 |
| Musculoskeletal | 1 |
| Neurological and mental health | 1 |
Registered clinical trials
9 of 17 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 19 · Not yet recruiting: 12 · Recruiting: 10 · Active, not recruiting: 4 · Unknown status: 1
Phase not applicable: 9 · Phase 1: 8 · Phase 1 / Phase 2: 4 · Phase 2: 9 · Phase 3: 11 · Phase 4: 5
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
Diabetes, obesity & metabolism · September 29, 2026 · Meta-analysis · cited 0 times · open access
PMID 42811393 · DOI 10.1111/dom.71400 · Reviews and meta-analyses
- Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.
BMJ medicine · August 27, 2026 · Meta-analysis · cited 0 times · open access
PMID 42688617 · DOI 10.1136/bmjmed-2026-003026 · Reviews and meta-analyses
- Efficacy and safety of mazdutide vs. dulaglutide in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Diabetology & metabolic syndrome · July 24, 2026 · Meta-analysis · cited 0 times · open access
PMID 42897592 · DOI 10.1186/s13098-026-02248-3 · Reviews and meta-analyses
- Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Diabetes, obesity & metabolism · July 6, 2026 · Meta-analysis · cited 1 times · open access
PMID 42410325 · DOI 10.1111/dom.71058 · Reviews and meta-analyses
- Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.
Diabetes, obesity & metabolism · March 10, 2026 · Meta-analysis · cited 3 times
PMID 41804840 · DOI 10.1111/dom.70643 · Reviews and meta-analyses
- Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.
Cardiology in review · February 19, 2026 · Meta-analysis · cited 1 times
PMID 41711462 · DOI 10.1097/crd.0000000000001209 · Reviews and meta-analyses
- Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials.
American journal of therapeutics · September 1, 2024 · Meta-analysis · cited 3 times
PMID 39292847 · DOI 10.1097/mjt.0000000000001756 · Reviews and meta-analyses
- Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials.
Endocrine · May 13, 2024 · Meta-analysis · cited 14 times
PMID 38740695 · DOI 10.1007/s12020-024-03857-6 · Reviews and meta-analyses
- Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.
Frontiers in endocrinology · February 14, 2024 · Meta-analysis · cited 30 times · open access
PMID 38440786 · DOI 10.3389/fendo.2024.1309118 · Reviews and meta-analyses
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
BMJ (Clinical research ed.) · July 8, 2026 · Systematic review · cited 8 times · open access
PMID 42419792 · DOI 10.1136/bmj-2026-372161 · Reviews and meta-analyses
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
The New England journal of medicine · May 25, 2025 · Randomized controlled trial · cited 122 times
PMID 40421736 · DOI 10.1056/nejmoa2411528 · Human clinical research
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.
Nature communications · December 14, 2023 · Randomized controlled trial · cited 118 times · open access
PMID 38092790 · DOI 10.1038/s41467-023-44067-4 · Human clinical research
- Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Diabetes care · January 1, 2024 · Randomized controlled trial · cited 90 times · open access
PMID 37943529 · DOI 10.2337/dc23-1287 · Human clinical research
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.
EClinicalMedicine · October 7, 2022 · Randomized controlled trial · cited 83 times · open access
PMID 36247927 · DOI 10.1016/j.eclinm.2022.101691 · Human clinical research
- IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.
EClinicalMedicine · August 13, 2021 · Randomized controlled trial · cited 63 times · open access
PMID 34430840 · DOI 10.1016/j.eclinm.2021.101088 · Human clinical research
Latest publications
- Effectiveness of the Dual GLP-1R/GCGR Agonist Mazdutide in GSD IXc: A Case Report.
Journal of clinical medicine · October 20, 2026 · Case report · cited 0 times · open access
PMID 42941641 · DOI 10.3390/jcm15208128 · Human clinical research
- The GLP-1R/GCGR Dual Agonist Mazdutide Attenuates Liver Steatosis and Decreases Circulating Cholesterol Levels in Mice With Metabolic Dysfunction-Associated Steatotic Liver Disease.
Diabetes, obesity & metabolism · October 14, 2026 · Animal study · cited 0 times · open access
PMID 42875732 · DOI 10.1111/dom.71435 · Animal studies
- The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus.
Obesity reviews : an official journal of the International Association for the Study of Obesity · October 11, 2026 · Review · cited 0 times · open access
PMID 42860310 · DOI 10.1111/obr.70228 · Reviews and meta-analyses
- Effects of Incretin-Based Pharmacotherapies on Lean Body Mass in Adults With Overweight, Obesity, or Type 2 Diabetes: A Systematic Review With Prespecified Network Meta-Analysis Feasibility Assessment.
Cureus · October 10, 2026 · Review · cited 0 times · open access
PMID 43005990 · DOI 10.7759/cureus.117738 · Reviews and meta-analyses
- Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
Diabetes, obesity & metabolism · September 29, 2026 · Meta-analysis · cited 0 times · open access
PMID 42811393 · DOI 10.1111/dom.71400 · Reviews and meta-analyses
- Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.
BMJ medicine · August 27, 2026 · Meta-analysis · cited 0 times · open access
PMID 42688617 · DOI 10.1136/bmjmed-2026-003026 · Reviews and meta-analyses
- Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.
The lancet. Diabetes & endocrinology · August 21, 2026 · Randomized controlled trial · cited 0 times
PMID 42628555 · DOI 10.1016/s2213-8587(26)00160-9 · Human clinical research
- Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary.
JAMA · August 4, 2026 · Editorial, letter or other · cited 0 times
PMID 42251596 · DOI 10.1001/jama.2026.8427 · Commentary and other
- Mazdutide and Orforglipron-New Evidence in Obesity and Diabetes.
JAMA · August 1, 2026 · Editorial, letter or other · cited 0 times
PMID 42251768 · DOI 10.1001/jama.2026.10443 · Commentary and other
- Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.
JAMA · August 1, 2026 · Randomized controlled trial · cited 8 times · open access
PMID 42251595 · DOI 10.1001/jama.2026.8142 · Human clinical research
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: IBI362; LY3305677; Mazdutide
((TITLE_ABS:"IBI362" OR CHEM:"IBI362" OR TITLE_ABS:"IBI 362" OR CHEM:"IBI 362") OR (TITLE_ABS:"LY3305677" OR CHEM:"LY3305677" OR TITLE_ABS:"LY 3305677" OR CHEM:"LY 3305677") OR (TITLE_ABS:"Mazdutide" OR CHEM:"Mazdutide")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). Mazdutide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/mazdutide